Lorecivivint clinical trials

How studies write it

Studies that test it under each name

Name

Lorecivivint: 7

Development codes

SM04690: 11

Studies by the year they started

12 studies that test it; most in 2020 (3)

Studies that test lorecivivint, by start year
Year	Studies
2014	1
2015	1
2017	2
2018	1
2019	2
2020	3
2021	1
2022	1

Who runs them

Industry 12 · Other 0

Biosplice Therapeutics, Inc. (12)

Often tested with

Tested in the same studies.

Triamcinolone Acetonide (1)

Studies

Open first, then newest update. How each study uses lorecivivint is read from its arms, and is right about nine times in ten.

Testing it · 12

Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Knee Osteoarthritis (STRIDES)CompletedPhase 3Biosplice Therapeutics, Inc.NCT05603754Written as Lorecivivint
3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee OsteoarthritisTerminatedPhase 3Biosplice Therapeutics, Inc.NCT04931667Written as Lorecivivint
A Long-Term Safety and Efficacy Study of Lorecivivint in Subjects With Osteoarthritis of the KneeTerminatedPhase 3Biosplice Therapeutics, Inc.NCT04520607Written as Lorecivivint
MRI Study to Evaluate the Safety and Efficacy of SM04690 for Knee OsteoarthritisTerminatedPhase 2Biosplice Therapeutics, Inc.NCT03706521Written as lorecivivint
Patient-Reported and Radiographic Outcomes in Evaluating Lorecivivint (SM04690) for the Treatment of Knee OsteoarthritisCompletedPhase 3Biosplice Therapeutics, Inc.NCT03928184Written as Lorecivivint
Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1)CompletedPhase 3Biosplice Therapeutics, Inc.NCT04385303Written as Lorecivivint
Safety and Bone Health Study of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisCompletedPhase 2Biosplice Therapeutics, Inc.NCT03727022Written as SM04690
A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisCompletedPhase 2Biosplice Therapeutics, Inc.NCT03122860Written as SM04690
A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis SubjectsCompletedPhase 2Biosplice Therapeutics, Inc.NCT02536833Written as SM04690
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy VolunteersCompletedPhase 1Biosplice Therapeutics, Inc.NCT04598542Written as Lorecivivint (LOR)
A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc DiseaseTerminatedPhase 1Biosplice Therapeutics, Inc.NCT03246399Written as SM04690
Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)CompletedPhase 1Biosplice Therapeutics, Inc.NCT02095548Written as SM04690, 0.03mg/2mL

Codes

What other systems call lorecivivint · ClinicalTrials.gg INT000954

MeSH (NLM) C000627701lorecivivintConfirmed ClinicalTrials.gov, NLM
UNII (FDA) 42EK42WHI5LORECIVIVINTConfirmed FDA, NLM, Wikidata
Wikidata Q105337463lorecivivintConfirmed FDA, NLM, Wikidata
NCI Thesaurus C166713LorecivivintOne source FDA
DrugBank DB14883One source Wikidata

System	Code	Name there	Checked by
MeSH (NLM)	C000627701	lorecivivint	Confirmed ClinicalTrials.gov, NLM
UNII (FDA)	42EK42WHI5	LORECIVIVINT	Confirmed FDA, NLM, Wikidata
Wikidata	Q105337463	lorecivivint	Confirmed FDA, NLM, Wikidata
NCI Thesaurus	C166713	Lorecivivint	One source FDA
DrugBank	DB14883	—	One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.